Regeneron Pharma (REGN) PT Cut to $389 at Morgan Stanley On Expense Creep
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $389.00 (from $420.00) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
